The global Parkinson’s disease drugs market was valued at $5,689.12 million in 2021, and is projected to reach $10,402.65 million by 2031, registering a CAGR of 6.2% from 2021 to 2031.
Parkinson's disease is a slowly progressing neurological condition that affects a few specific nerve cells (neurons) in the substantia nigra region of the brain. These cells produce dopamine, a chemical that transmits the signal in brain. Dopamine is essential for controlling body moves and cause of many Parkinson's disease symptoms is a decrease in dopamine level. People over the age of 50 are mostly affected by Parkinson’s disease. They may further experience mental & behavioral changes, sleep problems, depression, memory difficulties, and fatigue. The Parkinson’s disease drugs are used to treat Parkinson’s disease and reduces the symptoms of Parkinson’s disease. Signs and symptoms of Parkinson’s disease such as tremor, bradykinesia, rigid muscles, impaired posture and balance. Many of the symptoms are due to loss of neurons. The major risk factor is the age and others factors such as environmental factors, heredity, sex, exposure to toxins.
The major key factor such as increase in demand for Parkinson’s disease drugs is anticipated to increase globally during the forecast period, owing to rise in geriatric population and rising prevalence rate of Parkinson’s disease patients. Moreover, an increase in investments by key players toward R&D related to Parkinson’s disease drugs further drive growth of the market globally. However, adverse events associated with therapeutics of Parkinson’s disease drugs and high cost of treatment associated with Parkinson’s disease may limit the market growth. Conversely, high growth potential in untapped emerging countries and increasing R&D and continuous drug approval and product launch of Parkinson’s disease drugs are expected to offer lucrative growth opportunities for the key player in the market.
The Parkinson’s disease drugs market is segmented on the basis of drug class, route of administration, age group and region. On the basis of drug class, the market is classified into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors and others. On the basis of route of administration, it is segmented into oral, injection and transdermal. On the basis of age group, it is segmented into 50 or below 50 and above 50 years. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include AbbVie Inc., Amneal Pharmaceuticals Inc Cantata Bio, Biogen Inc., C.H. Boehringer Sohn Ko. KG, Eli Lilly company, Glaxosmithkline Plc, Gentech Healthcare, Intas Pharmaceuticals Limited, Orion Corporation, Novartis AG, Pfizer Inc., Square group, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Torrent Group, UCB pharma, Viatris Inc.
Parkinson's disease is a slowly progressing neurological condition that affects a few specific nerve cells (neurons) in the substantia nigra region of the brain. These cells produce dopamine, a chemical that transmits the signal in brain. Dopamine is essential for controlling body moves and cause of many Parkinson's disease symptoms is a decrease in dopamine level. People over the age of 50 are mostly affected by Parkinson’s disease. They may further experience mental & behavioral changes, sleep problems, depression, memory difficulties, and fatigue. The Parkinson’s disease drugs are used to treat Parkinson’s disease and reduces the symptoms of Parkinson’s disease. Signs and symptoms of Parkinson’s disease such as tremor, bradykinesia, rigid muscles, impaired posture and balance. Many of the symptoms are due to loss of neurons. The major risk factor is the age and others factors such as environmental factors, heredity, sex, exposure to toxins.
The major key factor such as increase in demand for Parkinson’s disease drugs is anticipated to increase globally during the forecast period, owing to rise in geriatric population and rising prevalence rate of Parkinson’s disease patients. Moreover, an increase in investments by key players toward R&D related to Parkinson’s disease drugs further drive growth of the market globally. However, adverse events associated with therapeutics of Parkinson’s disease drugs and high cost of treatment associated with Parkinson’s disease may limit the market growth. Conversely, high growth potential in untapped emerging countries and increasing R&D and continuous drug approval and product launch of Parkinson’s disease drugs are expected to offer lucrative growth opportunities for the key player in the market.
The Parkinson’s disease drugs market is segmented on the basis of drug class, route of administration, age group and region. On the basis of drug class, the market is classified into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors and others. On the basis of route of administration, it is segmented into oral, injection and transdermal. On the basis of age group, it is segmented into 50 or below 50 and above 50 years. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include AbbVie Inc., Amneal Pharmaceuticals Inc Cantata Bio, Biogen Inc., C.H. Boehringer Sohn Ko. KG, Eli Lilly company, Glaxosmithkline Plc, Gentech Healthcare, Intas Pharmaceuticals Limited, Orion Corporation, Novartis AG, Pfizer Inc., Square group, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Torrent Group, UCB pharma, Viatris Inc.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global spatial genomics and transcriptomics market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of spatial genomics and transcriptomics used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments
By Drug Class
- Decarboxylase Inhibitors
- Distribution Channel
- Hospital Pharmacies
- Drug stores and Retail Pharmacies
- Online Providers
- Dopamine Agonists
- COMT Inhibitors
- MAO-B Inhibitors
- Others
Route of Administration
- Oral
- Injection
- Transdermal
By Age Group
- 50 or below 50
- Above 50 years
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS
CHAPTER 5: PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP
CHAPTER 7: PARKINSON'S DISEASE DRUGS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report titled, “Parkinson’s Disease Drugs, by Drug class, Route of administration, Age group: Global Opportunity Analysis and Industry Forecast, 2021-2031," the global Parkinson’s disease market was valued at $5,689.12 million in 2021 and is projected to reach $10,402.65 million by 2031 registering a CAGR of 6.2% from 2021 to 2031.Parkinson’s disease affects neurological system and areas of body that are under the control of nerves. Parkinson’s disease is a neurodegenerative disease that mostly occurs above age of 50. Parkinson’s disease is also called as neurodegenerative disease or idiopathic Parkinsonism. The substantia nigra is a region of the brain where dopamine is produced and when cells of this part begin to die, it leads to Parkinson's disease. Thus, dopamine level is decreased in Parkinson’s disease patients.
The major key factors that drive the Parkinson's disease drugs market size is increase in prevalence of Parkinson’s disease. In addition, rise in R&D pipeline products and surge in demand for Parkinson’s disease drugs are further expected to boost the market growth during forecast period. Moreover, availability of wide range of Parkinson’s disease drugs and increase in geriatric population in developed countries are some Parkinson's disease drugs market trends further propels growth of market.
However, high-cost of treatment associated with Parkinson’s disease hamper growth of the Parkinson’s disease drugs market during the forecast period. Conversely, the ongoing medicine approvals and product launch of Parkinson’s disease drugs are expected to provide numerous opportunities during Parkinson's disease drugs market forecast.
COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The global Parkinson’s disease drugs market also declined in 2020 due to global economic recession led by COVID-19. However, Parkinson's disease drugs industry witness recovery in the year 2021, owing to increase in adoption of Parkinson’s disease drugs and rise in R&D pipeline products of Parkinson’s disease drugs.
The global Parkinson’s disease drugs market is segmented on the basis of drug class, route of administration, age group and region. By drug class, decarboxylase inhibitors, dopamine agonist, COMT inhibitors, MAO-B inhibitors and others. The decarboxylase inhibitors segment was the major revenue contributor in 2021, during the forecast period, owing to the surge in the high adoption of Parkinson’s disease drugs and increase in geriatric population as geriatric population more prone to Parkinson’s disease are the driving factor accelerating the growth of the decarboxylase inhibitors segment.
However, COMT inhibitor is projected to exhibit the fastest market growth during the forecast period due to rise in the R&D of pipeline products of COMT inhibitors is anticipated to fuel the growth of the market.
By route of administration, the market is segmented into oral, injection, and transdermal. The oral segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to advantages associated with oral routes such as easy to administer drugs and pain free.
On the basis of age group, the market is divided into 50 or below 50 and above 50 years. The above 50 years segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period, owing to increase in geriatric population which are more prone to Parkinson’s disease.
By region, the Parkinson’s disease drugs market are studied across North America, Asia-Pacific, Europe, and LAMEA. North America accounted for the largest Parkinson’s disease drugs market share in 2021, and is expected to remain dominant throughout the forecast period. This is attributed to factors such as availability of treatments for Parkinson’s disease, well-established regulations for approval and distribution of products & services. In addition, availability of wide range of Parkinson’s disease drugs and increase in geriatric population in this region propels growth of market.
However, Asia-Pacific is projected to register the highest CAGR of 8.8% during the forecast period, owing to increase in geriatric population. In addition, greater emphasis on research and development activities by both public and commercial organizations for the creation of innovative treatments for Parkinson's disease further drive growth of the region.
According to Onkar Sumant, Manager, Healthcare of the research firm, “rise in adoption of Parkinson’s disease drugs owing to increase in prevalence of Parkinson’s disease patients. In addition, rise in R&D pipeline products and surge in demand for Parkinson’s disease drugs are expected to boost the market growth during forecast period. Moreover, availability of wide range of Parkinson’s disease drugs and increase in geriatric population in developed countries propels growth of market.”
Key Findings of the Study
- Based on drug class, the decarboxylase inhibitors held largest market share in the global market in 2021. However, COMT inhibitors are anticipated to grow at the highest CAGR of 9.0% during Parkinson’s disease drugs market analysis.
- Based on route of administration, the oral segment held largest market share in 2021 and is expected to remain dominant throughout the forecast period.
- By age group, the above 50 years segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period.
- Based on Region, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 8.8% during the forecast period.
Companies Mentioned
- AbbVie Inc.
- Amneal Pharmaceuticals, Inc.
- Biogen Inc.
- C.H. Boehringer Sohn Ko. KG
- Eli Lilly and Company
- Gentech Healthcare
- GlaxoSmithKline Plc
- Intas Pharmaceuticals Limited
- Novartis AG
- Orion Corporation
- Pfizer Inc.
- Square group
- Sun Pharmaceutical Industries
- Teva Pharmaceuticals
- Torrent Group
- UCB
- Viatris Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 251 |
| Published | September 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 5689.12 million |
| Forecasted Market Value ( USD | $ 10402.65 million |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
Related Reports
Anti-Parkinson Drugs Global Market Report 2024
- Report
- 175 Pages
- Global
From
Parkinson's disease - Pipeline Insight, 2024
- Drug Pipelines
- 230 Pages
- Global
From
Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032
- Report
- 285 Pages
- Global
From
Parkinson's Disease Treatment - Global Strategic Business Report
- Report
- 93 Pages
- Global
From
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
